Creekmur Asset Management LLC Acquires 964 Shares of Cencora, Inc. (NYSE:COR)

Creekmur Asset Management LLC increased its position in Cencora, Inc. (NYSE:COR - Free Report) by 3,707.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 990 shares of the company's stock after buying an additional 964 shares during the period. Creekmur Asset Management LLC's holdings in Cencora were worth $275,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of COR. Kingsview Wealth Management LLC grew its holdings in Cencora by 21.1% in the first quarter. Kingsview Wealth Management LLC now owns 2,620 shares of the company's stock valued at $728,000 after purchasing an additional 457 shares during the period. Bailard Inc. acquired a new stake in shares of Cencora in the first quarter worth $219,000. Graypoint LLC increased its position in shares of Cencora by 13.8% in the first quarter. Graypoint LLC now owns 1,442 shares of the company's stock worth $401,000 after acquiring an additional 175 shares in the last quarter. Dynasty Wealth Management LLC increased its position in shares of Cencora by 44.5% in the first quarter. Dynasty Wealth Management LLC now owns 12,034 shares of the company's stock worth $3,347,000 after acquiring an additional 3,707 shares in the last quarter. Finally, Verdence Capital Advisors LLC increased its position in shares of Cencora by 4.2% in the first quarter. Verdence Capital Advisors LLC now owns 29,853 shares of the company's stock worth $8,302,000 after acquiring an additional 1,217 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the transaction, the chairman owned 311,913 shares of the company's stock, valued at $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer directly owned 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,127 shares of company stock worth $9,812,296. Insiders own 10.80% of the company's stock.

Cencora Price Performance

Shares of NYSE:COR traded down $1.65 during trading hours on Friday, hitting $292.73. 1,049,106 shares of the company's stock traded hands, compared to its average volume of 1,505,314. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35. The company's fifty day simple moving average is $292.38 and its two-hundred day simple moving average is $272.41. The company has a market cap of $56.74 billion, a price-to-earnings ratio of 33.96, a price-to-earnings-growth ratio of 1.45 and a beta of 0.57. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same period last year, the company posted $3.80 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

Wall Street Analyst Weigh In

COR has been the subject of several analyst reports. Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Jefferies Financial Group increased their price objective on shares of Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research note on Monday, June 30th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an "equal weight" rating in a research note on Wednesday. UBS Group increased their price objective on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Finally, Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $274.00 to $337.00 in a report on Tuesday, June 3rd. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $309.83.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.